Oral Antiplatelet Therapy for Secondary Prevention of Non-Cardioembolic Ischemic Cerebrovascular Events

Oral Antiplatelet Therapy for Secondary Prevention of Non-Cardioembolic Ischemic Cerebrovascular Events

Stroke is the leading cause of disability and mortality worldwide. After an acute cerebrovascular ischemia, recurrent vascular events, including recurrent stroke or transient ischemic accidents (TIA), occur in around 20% of cases within the first 3 months. In order to minimize this percentage, antip...

Full description

Bibliographic Details
Main Authors: Leonardo De Luca, Elisa Bellettini, Dario Di Maio, Enrico Natale, Rita Lucia Putini, Sabrina Anticoli, Furio Colivicchi, Paolo Calabrò, Francesco Musumeci, Domenico Gabrielli
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Journal of Clinical Medicine
Subjects:
antiplatelet therapy
aspirin
clopidogrel
ticagrelor
stroke
TIA
Online Access:https://www.mdpi.com/2077-0383/10/8/1721

Internet

https://www.mdpi.com/2077-0383/10/8/1721

Similar Items